Targeted therapy for advanced non-small cell lung cancers: historical perspective, current practices, and future development

Curr Probl Cancer. 2009 Mar-Apr;33(2):73-111. doi: 10.1016/j.currproblcancer.2009.03.001.

Authors

Devalingam Mahalingam¹, Alain Mita, Monica M Mita, Steffan T Nawrocki, Francis J Giles

Affiliation

¹ Institute of Drug Development, Division of Cancer Research and Therapy Center, University of Texas Health Science Center, San Antonio, Texas, USA.

PMID: 19409299
DOI: 10.1016/j.currproblcancer.2009.03.001

No abstract available

Publication types

Review

MeSH terms

Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Apoptosis / drug effects
Bayes Theorem
Bevacizumab
Carcinoma, Non-Small-Cell Lung / therapy*
Drug Delivery Systems / trends*
Histone Deacetylases / drug effects
Humans
Lung Neoplasms / therapy*
Neovascularization, Pathologic / drug therapy
Practice Patterns, Physicians' / trends
Protein-Tyrosine Kinases / antagonists & inhibitors
Radiotherapy, Adjuvant
Receptor, IGF Type 1 / drug effects
Vascular Endothelial Growth Factor A / drug effects

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Vascular Endothelial Growth Factor A
Bevacizumab
Protein-Tyrosine Kinases
Receptor, IGF Type 1
Histone Deacetylases